cisplatin,avelumab,domvanalimab,zimberelimab,pembrolizumab,sacituzumab govitecan
merck,otsuka,gilead sciences,pfizer,arcus biosciences
[' cis ', 'trophy,u-01', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
 presenting primary analysis of trophy-u-01 cohort 2! cis ineligible, post cpi #38 patients, 29% liver mets prior ev 18% orr 32%; 54% in patients without prior ev or platinum #gu23 
GU Oncologist/Researcher @UCSD interested in #CtDNA #MRD #BladderCancer. Views are my own.